Hirschsprung-associated Enterocolitis: Prevention and Therapy

Semin Pediatr Surg. 2012 Nov;21(4):328-35. doi: 10.1053/j.sempedsurg.2012.07.007.

Abstract

Hirschsprung-associated enterocolitis remains the greatest cause of morbidity and mortality in children with Hirschsprung disease. This chapter details the various approaches used to treat and prevent this disease process. This includes prevention of complications, such as stricture formation, prophylaxis with rectal washouts, and identification of high-risk individuals. The chapter also details approaches to diagnose Hirschsprung-associated enterocolitis as well as to exclude other etiologies.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Anal Canal / surgery
  • Anti-Bacterial Agents / therapeutic use
  • Botulinum Toxins / therapeutic use
  • Combined Modality Therapy
  • Constriction, Pathologic / etiology
  • Constriction, Pathologic / prevention & control
  • Dilatation
  • Enterocolitis / diagnosis
  • Enterocolitis / etiology
  • Enterocolitis / prevention & control
  • Enterocolitis / therapy*
  • Enterostomy
  • Hirschsprung Disease / complications*
  • Hirschsprung Disease / diagnosis
  • Hirschsprung Disease / surgery
  • Humans
  • Inflammatory Bowel Diseases / diagnosis
  • Inflammatory Bowel Diseases / etiology
  • Neuromuscular Agents / therapeutic use
  • Postoperative Complications / prevention & control
  • Probiotics / therapeutic use
  • Recurrence
  • Risk Assessment
  • Risk Factors
  • Therapeutic Irrigation

Substances

  • Anti-Bacterial Agents
  • Neuromuscular Agents
  • Botulinum Toxins